This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koukourakis, M. I. Articles by Harris, A. L. Search for Related Content PubMed PubMed Citation Articles by Koukourakis, M. I. Articles by Harris, A. L.

Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer¹

Tumour and Angiogenesis Research Group: Department of Radiotherapy/Oncology and Laboratory of Cancer Biology, University Hospital of Iraklion, Iraklion 71110, Crete, Greece [M. I. K., S. K., V. G.]; Department of Pathology, Democritus University of Thrace, Alexandroupolis 68100, Greece [A. G., E. S.]; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75235-9041 [P. E. T., R. A. B.]; and Departments of Cellular Science and Imperial Cancer Research Fund Medical Oncology Unit, Oxford Radcliffe Hospital, Headington, Oxford, OX3 7LJ, United Kingdom [K. C. G, A. L. H.]

Vascular endothelial growth factor (VEGF) is an important angiogenic factor, linked to poor outcome in human malignancies including non-small cell lung carcinoma (NSCLC). We used the 11B5 monoclonal antibody recognizing the VEGF/KDR complex (R. A. Brekken et al., Cancer Res., 58: 1952–1959, 1998) to assess the VEGF expression in cancer cells and the VEGF/KDR activated microvessel density (aMVD) in early operable NSCLC. The JC70 anti-CD31 monoclonal antibody was used to assess the standard MVD (sMVD). The aMVD was significantly higher in the invading front of the tumors and in the normal lung adjacent to the tumors as compared with normal lung distant to the tumor or to inner tumor areas (P < 0.0002). The sMVD was higher in the normal lung and decreased from the invading front to inner tumor areas (P < 0.0001). However, the vascular activation (aMVD:sMVD) was 4–6 times higher in the tumor areas as compared with lung from normal individuals (36–58% versus 9%; P < 0.0001). Fibroblast 11B5 reactivity, noted in 25% of cases, correlated with high aMVD and sMVD in the inner tumor areas. Multivariate analysis showed that aMVD was the most potent and independent prognostic factor (P = 0.001; t-ratio, 3.28). It is concluded that intense VEGF/KDR angiogenic pathway activation is a tumor-specific feature in more than 50% of NSCLC cases and is associated with poor postoperative outcome. Clinical trials involving targeting of the VEGF/KDR-positive vasculature with specific antibodies, such as 11B5, are, therefore, encouraged.

This article has been cited by other articles:

				I. H. Ozbudak, G. Ozbilim, I. Kucukosmanoglu, L. Dertsiz, and A. Demircan Vascular Endothelial Growth Factor Expression and Neovascularization in Non--Small Cell Lung Carcinoma International Journal of Surgical Pathology, October 1, 2009; 17(5): 390 - 395. [Abstract] [PDF]

				C. Chetty, S. S. Lakka, P. Bhoopathi, S. Kunigal, R. Geiss, and J. S. Rao Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer Cancer Res., June 15, 2008; 68(12): 4736 - 4745. [Abstract] [Full Text] [PDF]

				P. Sardari Nia, C. Colpaert, P. Vermeulen, J. Weyler, F. Pezzella, P. Van Schil, and E. Van Marck Different Growth Patterns of Non-Small Cell Lung Cancer Represent Distinct Biologic Subtypes Ann. Thorac. Surg., February 1, 2008; 85(2): 395 - 405. [Abstract] [Full Text] [PDF]

				T. Donnem, S. Al-Saad, K. Al-Shibli, M. P. Delghandi, M. Persson, M. N. Nilsen, L.-T. Busund, and R. M. Bremnes Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non Small Cell Lung Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6649 - 6657. [Abstract] [Full Text] [PDF]

				G. Korpanty, J. G. Carbon, P. A. Grayburn, J. B. Fleming, and R. A. Brekken Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature Clin. Cancer Res., January 1, 2007; 13(1): 323 - 330. [Abstract] [Full Text] [PDF]

				C. Cao, J. M. Albert, L. Geng, P. S. Ivy, A. Sandler, D. H. Johnson, and B. Lu Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer Cancer Res., December 1, 2006; 66(23): 11409 - 11415. [Abstract] [Full Text] [PDF]

				M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. C. Gatter, and A. L. Harris Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway--A Report of the Tumour Angiogenesis Research Group J. Clin. Oncol., September 10, 2006; 24(26): 4301 - 4308. [Abstract] [Full Text] [PDF]

				L Li, Y-Z Yuan, J Lu, L Xia, Y Zhu, Y-P Zhang, and M-M Qiao Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice Gut, February 1, 2006; 55(2): 259 - 265. [Abstract] [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				L. S. Rosen VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances Oncologist, June 1, 2005; 10(6): 382 - 391. [Abstract] [Full Text] [PDF]

				S. Mocellin, M. Provenzano, C. R. Rossi, P. Pilati, R. Scalerta, M. Lise, and D. Nitti Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity Clin. Cancer Res., October 15, 2004; 10(20): 6879 - 6886. [Abstract] [Full Text] [PDF]

				W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J. Clin. Pathol., September 1, 2004; 57(9): 965 - 969. [Abstract] [Full Text] [PDF]

				A. Giatromanolaki, M. I. Koukourakis, H. M. Sowter, E. Sivridis, S. Gibson, K. C. Gatter, and A. L. Harris BNIP3 Expression Is Linked with Hypoxia-Regulated Protein Expression and with Poor Prognosis in Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5566 - 5571. [Abstract] [Full Text] [PDF]

				R. S. Herbst and A. B. Sandler Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab? Oncologist, June 1, 2004; 9(suppl_1): 19 - 26. [Abstract] [Full Text] [PDF]

				M. I. Koukourakis, A. Giatromanolaki, R. A. Brekken, E. Sivridis, K. C. Gatter, A. L. Harris, and E. H. Sage Enhanced Expression of SPARC/Osteonectin in the Tumor-associated Stroma of Non-Small Cell Lung Cancer Is Correlated with Markers of Hypoxia/ Acidity and with Poor Prognosis of Patients Cancer Res., September 1, 2003; 63(17): 5376 - 5380. [Abstract] [Full Text] [PDF]

				F. Benavides, M. F. Starost, M. Flores, I. B. Gimenez-Conti, J.-L. Guenet, and C. J. Conti Impaired Hair Follicle Morphogenesis and Cycling with Abnormal Epidermal Differentiation in nackt Mice, a Cathepsin L-Deficient Mutation Am. J. Pathol., August 1, 2002; 161(2): 693 - 703. [Abstract] [Full Text] [PDF]

				P. Guo, L. Xu, S. Pan, R. A. Brekken, S.-T. Yang, G. B. Whitaker, M. Nagane, P. E. Thorpe, J. S. Rosenbaum, H.-J. Su Huang, et al. Vascular Endothelial Growth Factor Isoforms Display Distinct Activities in Promoting Tumor Angiogenesis at Different Anatomic Sites Cancer Res., December 1, 2001; 61(23): 8569 - 8577. [Abstract] [Full Text] [PDF]

				J. Ma, S. Pulfer, S. Li, J. Chu, K. Reed, and J. M. Gallo Pharmacodynamic-mediated Reduction of Temozolomide Tumor Concentrations by the Angiogenesis Inhibitor TNP-470 Cancer Res., July 1, 2001; 61(14): 5491 - 5498. [Abstract] [Full Text] [PDF]